Method for treating abdominal discomfort
View Patent ↗A method for treating irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E 1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E 1 , or a salt, ether, ester or amide thereof, to the subject. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject includes administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E 1 or 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E 1 , or a salt, ether, ester or amide thereof, to the subject.
1. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E 1 , or a salt, ether, ester or amide thereof, to the subject.
2. The method as described in claim 1 , which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E 1 , or a pharmaceutically acceptable salt, ester or amide thereof.
3. The method as described in claim 1 , which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μg/kg per day or a 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E 1 compound.
4. A method for treating as described in claim 2 , wherein the administration is in the amount of 0.1-10 μg/kg per day.
5. The method as described in claim 1 , which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 μ g/kg per day.
6. The method as described in claim 5 , wherein the administration is at the amount of 0.1-10 μg/kg per day.
7. A method for treating irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E 1 or a salt, ether, ester or amide thereof, to the subject.
8. The method as described in claim 7 , which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E 1 , or a pharmaceutically acceptable salt, ester or amide thereof.
9. The method for treating irritable bowel syndrome in a as described in claim 8 , which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μg/kg per day.
10. The method as described in claim 8 , wherein the administration is in the amount of 0.1-10 μg/kg per day.
11. The method as described in claim 7 , which comprises systemic administration 1-4 times per day or continuous administration at the amount of 0.01-100 μg/kg per day.
12. The method as described in claim 7 , wherein the administration is at the amount of 0.1-10 μg/kg per day.
13. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E 1 , or a salt, ether, ester or amide thereof, to the subject.
14. The method as described in claim 13 , which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-18-methyl-prostaglandin E 1 , or a pharmaceutically acceptable salt, ester or amide thereof.
15. The method as described in claim 14 , which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μg/kg per day.
16. The method as described in claim 13 , which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μg/kg per day.
17. The method as described in claim 13 , wherein the administration is in the amount of 0.1-10 μg/kg per day.
18. A method for treating abdominal discomfort associated with irritable bowel syndrome in a mammalian subject, which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro prostaglandin E 1 , or a salt, ether, ester or amide thereof, to the subject.
19. The method as described in claim 18 , which comprises administering an effective amount of 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E 1 , or a pharmaceutically acceptable salt, ester or amide thereof.
20. The method as described in claim 19 , which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μg/kg per day.
21. The method as described in claim 18 , which comprises systemic administration 1-4 times per day or continuous administration in the amount of 0.01-100 μg/kg per day.
22. The method as described in claim 18 , wherein the administration is in the amount of 0.1-10 μg/kg per day.